Anti-poverty vaccines, or those that target NTDs, serve to improve human health and support economic development in developing nations predominantly affected by NTDs. Despite these significant benefits, there is a starking lack of incentive for pharmaceutical companies to develop such vaccines. Without an available commercial market for these vaccines, pharmaceutical companies are unwilling to make the necessary investment in research. However, there are various incentives, like review vouchers, which are being used to increase interest to upscale the manufacturing of these vaccines.